ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


Replay of the Leukemia & Lymphoma Society's TAP event: Dr. Stephan Braun, our CMO, highlights ICT01 data presented at ASH 2024
Science & Medicine 
Read more
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Meeting Annual Meeting
Science & Medicine 
Read more
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
Science & Medicine 
Read more

AACR 2025

From  Apr 25, 2025  to  Apr 30, 2025 

Read more

ASCO ANNUAL MEETING 2025

From  May 30, 2025  to  Jun 03, 2025 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news